Skip to content
Menu

Ocugen, Inc. OCGN

Full chart Compare
Set alert

Price alert · OCGN

All alert types
0.77 USD -0.05 (-6.62%)

Regular-session close

0.77 0.00 -0.39%

After hours · Nov 16, 7:21 PM ET

0.7411 Day range 0.82
0.691 52-week range 2.73
YTD
-42.74%
1 year
-35.04%

Discussion (3611)

Nicole Meyer OCGN 2 years ago #451

$FLGC and $OCGN are my absolute winners today!!! Snd probably tomorrow too if it continues like this!!! But do your own DD and this is no financial advice

VICKY HANUKA OCGN 2 years ago #452

That’s you chance to make money if you buy 3,000 shares where you gonna make 1,00,000 $ a year be smart do research and see it will go up to 38$

VICKY HANUKA OCGN 2 years ago #453

I bought MSTR at 700$ when it went down to 1230 people was scared i bought more now I made 500$ on the top of 1,230 just time and patience you gonna be a winner

VICKY HANUKA OCGN 2 years ago #456

I have lots of time it will go with in 12 months to 38$ I have 3,000 shares I’ll make 100,000 $ no rush

VICKY HANUKA OCGN 2 years ago #457

Don’t sell it’s very good company it will go mach higher

VICKY HANUKA OCGN 2 years ago #458

Ocugen (OCGN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on the stock and has a $7.00 price target.

VICKY HANUKA OCGN 2 years ago #459

Ocugen (OCGN) was up more than 11% after a federal appeals court upheld a lower-court decision, dismissing allegations of misleading shareholders with its statements about a prospective COVID-19 vaccine and its approvals in the US.

VICKY HANUKA OCGN 2 years ago #460

03:37 PM EDT, 03/22/2024 (MT Newswires) -- Ocugen (OCGN) shares surged nearly 19% Friday, a day after a federal appeals court upheld a lower-court decision, dismissing allegations of misleading shareholders with its statements about a prospective COVID-19 vaccine and its approvals in the US.

Plaintiffs alleged that Ocugen made statements suggesting the US Food and Drug Administration would approve its Covaxin vaccine candidate based on results from trial conducted in India. The agency in June 2021 instead said Ocugen would need to start US trials, sending its shares plunging.

The US Court of Appeals for the Third Circuit ruled the company provided ample warning about the risks with FDA approval, writing that using facts that only became known later "does not substitute for contemporaneous knowledge in a securities fraud case."

Price: 1.59, Change: +0.25, Percent Change: +18.75

Sign in to join the discussion